Top

Published in:

01-08-2014 | Review Paper

Small But Mighty: Microparticles as Mediators of Tumor Progression

Authors: Tali Voloshin, Ella Fremder, Yuval Shaked

Published in: Cancer Microenvironment | Issue 1-2/2014

Abstract

A wide spectrum of both normal and diseased cell types shed extracellular vesicles that facilitate intercellular communication without direct cell-to-cell contact. Microparticles (MPs) are a subtype of extracellular vesicles that participate in multiple biological processes. They carry abundant bioactive molecules including different forms of nucleic acids and proteins that can markedly modulate cellular behavior. MPs are involved in several hallmarks of cancer such as drug resistance, thrombosis, immune evasion, angiogenesis, tumor invasion and metastasis. Such MPs originate from either cancer or other host cells. As MPs are secreted and can be detected in various body fluids, they can be used as potential diagnostic and prognostic biomarkers as well as vehicles for delivery of cytotoxic drugs. This review summarizes accumulating evidence on the biological properties of MPs in cancer, with reference to their potential usage in clinical settings.

Smalley DM, Sheman NE, Nelson K, Theodorescu D (2008) Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res 7(5):2088–2096. doi:10.1021/pr700775x PubMed

Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A (2009) Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 101(3):439–451PubMed

Zachau AC, Landen M, Mobarrez F, Nybom R, Wallen H, Wetterberg L (2012) Leukocyte-derived microparticles and scanning electron microscopic structures in two fractions of fresh cerebrospinal fluid in amyotrophic lateral sclerosis: a case report. J Med Case Rep 6(1):274. doi:10.1186/1752-1947-6-274 PubMedCentralPubMed

Boilard E, Blanco P, Nigrovic PA (2012) Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 8(9):534–542. doi:10.1038/nrrheum.2012.118 PubMed

El Andaloussi S, Mager I, Breakefield XO, Wood MJ (2013) Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 12(5):347–357. doi:10.1038/nrd3978

Vlassov AV, Magdaleno S, Setterquist R, Conrad R (2012) Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 1820(7):940–948. doi:10.1016/j.bbagen.2012.03.017 PubMed

Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6(3):267–283. doi:10.1586/epr.09.17 PubMed

Nickel W (2005) Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 6(8):607–614. doi:10.1111/j.1600-0854.2005.00302.x PubMed

Cocucci E, Racchetti G, Meldolesi J (2009) Shedding microvesicles: artefacts no more. Trends Cell Biol 19(2):43–51. doi:10.1016/j.tcb.2008.11.003 PubMed

10.

Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D’Souza-Schorey C, Freeman MR (2012) Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol 181(5):1573–1584. doi:10.1016/j.ajpath.2012.07.030 PubMedCentralPubMed

11.

Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10(5):619–624. doi:10.1038/ncb1725 PubMed

12.

Lee TH, D’Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J (2011) Microvesicles as mediators of intercellular communication in cancer–the emerging science of cellular ‘debris’. Semin Immunopathol 33(5):455–467. doi:10.1007/s00281-011-0250-3 PubMed

13.

Beyer C, Pisetsky DS (2010) The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol 6(1):21–29. doi:10.1038/nrrheum.2009.229 PubMed

14.

Thery C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2(8):569–579. doi:10.1038/nri855 PubMed

15.

Piccin A, Murphy WG, Smith OP (2007) Circulating microparticles: pathophysiology and clinical implications. Blood Rev 21(3):157–171. doi:10.1016/j.blre.2006.09.001 PubMed

16.

Connor DE, Exner T, Ma DD, Joseph JE (2010) The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 103(5):1044–1052. doi:10.1160/TH09-09-0644 PubMed

17.

Dasgupta SK, Guchhait P, Thiagarajan P (2006) Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Transl Res 148(1):19–25. doi:10.1016/j.lab.2006.03.006 PubMed

18.

Thery C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9(8):581–593. doi:10.1038/nri2567 PubMed

19.

van der Pol E, Hoekstra AG, Sturk A, Otto C, van Leeuwen TG, Nieuwland R (2010) Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost 8(12):2596–2607. doi:10.1111/j.1538-7836.2010.04074.x PubMed

20.

Orozco AF, Lewis DE (2010) Flow cytometric analysis of circulating microparticles in plasma. Cytometry A 77(6):502–514. doi:10.1002/cyto.a.20886 PubMedCentralPubMed

21.

Ziegler U, Groscurth P (2004) Morphological features of cell death. News Physiol Sci 19:124–128PubMed

22.

Hengartner MO (2001) Apoptosis: corralling the corpses. Cell 104(3):325–328PubMed

23.

Wang JG, Geddings JE, Aleman MM, Cardenas JC, Chantrathammachart P, Williams JC, Kirchhofer D, Bogdanov VY, Bach RR, Rak J, Church FC, Wolberg AS, Pawlinski R, Key NS, Yeh JJ, Mackman N (2012) Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 119(23):5543–5552. doi:10.1182/blood-2012-01-402156 PubMedCentralPubMed

24.

Skeppholm M, Mobarrez F, Malmqvist K, Wallen H (2012) Platelet-derived microparticles during and after acute coronary syndrome. Thromb Haemost 107(6):1122–1129. doi:10.1160/TH11-11-0779 PubMed

25.

Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, de Marchena E, Ahn YS (2003) High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 145(6):962–970. doi:10.1016/S0002-8703(03)00103-0 PubMed

26.

Garcia S, Chirinos J, Jimenez J, Del Carpio MF, Canoniero M, Jy W, Horstman L, Ahn Y (2005) Phenotypic assessment of endothelial microparticles in patients with heart failure and after heart transplantation: switch from cell activation to apoptosis. J Heart Lung Transplant 24(12):2184–2189. doi:10.1016/j.healun.2005.07.006 PubMed

27.

Simak J, Gelderman MP, Yu H, Wright V, Baird AE (2006) Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost 4(6):1296–1302. doi:10.1111/j.1538-7836.2006.01911.x PubMed

28.

Sabatier F, Darmon P, Hugel B, Combes V, Sanmarco M, Velut JG, Arnoux D, Charpiot P, Freyssinet JM, Oliver C, Sampol J, Dignat-George F (2002) Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 51(9):2840–2845PubMed

29.

Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, Horstman LL, Soriano AO, Zambrano JP, Ahn YS (2005) Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 45(9):1467–1471. doi:10.1016/j.jacc.2004.12.075 PubMed

30.

Alijotas-Reig J, Palacio-Garcia C, Llurba E, Vilardell-Tarres M (2013) Cell-derived microparticles and vascular pregnancy complications: a systematic and comprehensive review. Fertil Steril 99(2):441–449. doi:10.1016/j.fertnstert.2012.10.009 PubMed

31.

Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, Perez C, Saez C, Panes O, Matus V, Mezzano D (2006) Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost 95(1):94–99PubMed

32.

Mobarrez F, Nybom R, Johansson V, Hultman CM, Wallen H, Landen M, Wetterberg L (2013) Microparticles and microscopic structures in three fractions of fresh cerebrospinal fluid in schizophrenia: case report of twins. Schizophr Res 143(1):192–197. doi:10.1016/j.schres.2012.10.030 PubMed

33.

Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K (2006) Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 103(30):11172–11177. doi:10.1073/pnas.0603838103 PubMedCentralPubMed

34.

Zhang HG, Grizzle WE (2013) Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol. doi:10.1016/j.ajpath.2013.09.027

35.

Azmi AS, Bao B, Sarkar FH (2013) Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev 32(3–4):623–642. doi:10.1007/s10555-013-9441-9 PubMed

36.

Wolf P (1967) The nature and significance of platelet products in human plasma. Br J Haematol 13(3):269–288PubMed

37.

Varon D, Shai E (2009) Role of platelet-derived microparticles in angiogenesis and tumor progression. Discov Med 8(43):237–241PubMed

38.

Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J (2009) Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A 106(10):3794–3799. doi:10.1073/pnas.0804543106 PubMedCentralPubMed

39.

Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119(1):60–68. doi:10.1016/j.amjmed.2005.06.058 PubMed

40.

Amer MH (2013) Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res 5:165–178. doi:10.2147/CMAR.S47094 PubMedCentralPubMed

41.

Yu JL, Rak JW (2004) Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2(11):2065–2067. doi:10.1111/j.1538-7836.2004.00972.x PubMed

42.

Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH, Francis JL (2008) Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 6(9):1517–1524. doi:10.1111/j.1538-7836.2008.02987.x PubMed

43.

Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW (2005) Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105(4):1734–1741. doi:10.1182/blood-2004-05-2042 PubMed

44.

Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C (2009) Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 206(9):1913–1927. doi:10.1084/jem.20082297 PubMedCentralPubMed

45.

Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111PubMed

46.

Wicha MS (2006) Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res 12(19):5606–5607PubMed

47.

Milsom C, Magnus N, Meehan B, Al-Nedawi K, Garnier D, Rak J (2009) Tissue factor and cancer stem cells: is there a linkage? Arterioscler Thromb Vasc Biol 29(12):2005–2014. doi:10.1161/ATVBAHA.108.177444 PubMed

48.

Garnier D, Milsom C, Magnus N, Meehan B, Weitz J, Yu J, Rak J (2010) Role of the tissue factor pathway in the biology of tumor initiating cells. Thromb Res 125(Suppl 2):S44–S50. doi:10.1016/S0049-3848(10)70012-8 PubMed

49.

Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, Grau GE (2009) Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 23(9):1643–1649. doi:10.1038/leu.2009.76 PubMed

50.

Pasquier J, Galas L, Boulange-Lecomte C, Rioult D, Bultelle F, Magal P, Webb G, Le Foll F (2012) Different modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 breast cancer cells. J Biol Chem 287(10):7374–7387. doi:10.1074/jbc.M111.312157 PubMedCentralPubMed

51.

Jaiswal R, Luk F, Dalla PV, Grau GE, Bebawy M (2013) Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS One 8(4):e61515. doi:10.1371/journal.pone.0061515 PubMedCentralPubMed

52.

Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R, Grau GE, Bebawy M (2012) Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J 26(1):420–429. doi:10.1096/fj.11-186817 PubMed

53.

Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, Ratajczak MZ (2006) Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20(5):847–856. doi:10.1038/sj.leu.2404132 PubMed

54.

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654–659. doi:10.1038/ncb1596 PubMed

55.

Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J (2011) Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2:180. doi:10.1038/ncomms1180 PubMedCentralPubMed

56.

Poutsiaka DD, Taylor DD, Levy EM, Black PH (1985) Inhibition of recombinant interferon-gamma-induced Ia antigen expression by shed B16 F10 melanoma cell membrane vesicles. J Immunol 134(1):145–150PubMed

57.

Dolo V, Pizzurro P, Ginestra A, Vittorelli ML (1995) Inhibitory effects of vesicles shed by human breast carcinoma cells on lymphocyte 3H-thymidine incorporation, are neutralised by anti TGF-beta antibodies. J Submicrosc Cytol Pathol 27(4):535–541PubMed

58.

Albanese J, Meterissian S, Kontogiannea M, Dubreuil C, Hand A, Sorba S, Dainiak N (1998) Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood 91(10):3862–3874PubMed

59.

Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE (2010) Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 115(9):1755–1764PubMedCentralPubMed

60.

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186. doi:10.1056/NEJM197111182852108 PubMed

61.

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302):964–967PubMed

62.

Taraboletti G, D’Ascenzo S, Giusti I, Marchetti D, Borsotti P, Millimaggi D, Giavazzi R, Pavan A, Dolo V (2006) Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia 8(2):96–103. doi:10.1593/neo.05583 PubMedCentralPubMed

63.

Millimaggi D, Mari M, D’Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, Dolo V (2007) Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 9(4):349–357PubMedCentralPubMed

64.

Taverna S, Ghersi G, Ginestra A, Rigogliuso S, Pecorella S, Alaimo G, Saladino F, Dolo V, Dell’Era P, Pavan A, Pizzolanti G, Mignatti P, Presta M, Vittorelli ML (2003) Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. J Biol Chem 278(51):51911–51919. doi:10.1074/jbc.M304192200 PubMed

65.

Yu J, May L, Milsom C, Anderson GM, Weitz JI, Luyendyk JP, Broze G, Mackman N, Rak J (2008) Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 28(11):1975–1981. doi:10.1161/ATVBAHA.108.175083 PubMedCentralPubMed

66.

Pasquier J, Thawadi HA, Ghiabi P, Abu-Kaoud N, Maleki M, Guerrouahen BS, Vidal F, Courderc B, Ferron G, Martinez A, Al Sulaiti H, Gupta R, Rafii S, Rafii A (2014) Microparticles mediated cross-talk between tumoral and endothelial cells promote the constitution of a pro-metastatic vascular niche through Arf6 up regulation. Cancer Microenviron. doi:10.1007/s12307-013-0142-2 PubMed

67.

Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, Gho YS (2002) Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res 62(21):6312–6317PubMed

68.

Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, Brenner B, Shaked Y (2013) Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: A process regulated by osteopontin. Int J Cancer. doi:10.1002/ijc.28678

69.

Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D (2005) Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 67(1):30–38. doi:10.1016/j.cardiores.2005.04.007 PubMed

70.

Kim HK, Song KS, Chung JH, Lee KR, Lee SN (2004) Platelet microparticles induce angiogenesis in vitro. Br J Haematol 124(3):376–384PubMed

71.

Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ (2005) Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113(5):752–760. doi:10.1002/ijc.20657 PubMed

72.

Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ (2006) Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 46(7):1199–1209. doi:10.1111/j.1537-2995.2006.00871.x PubMed

73.

Aharon A, Tamari T, Brenner B (2008) Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 100(5):878–885PubMed

74.

Taraboletti G, D’Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V (2002) Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 160(2):673–680. doi:10.1016/S0002-9440(10)64887-0 PubMedCentralPubMed

75.

Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G (2007) Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 110(7):2440–2448. doi:10.1182/blood-2007-03-078709 PubMed

76.

Yang C, Mwaikambo BR, Zhu T, Gagnon C, Lafleur J, Seshadri S, Lachapelle P, Lavoie JC, Chemtob S, Hardy P (2008) Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways. Am J Physiol Regul Integr Comp Physiol 294(2):R467–R476. doi:10.1152/ajpregu.00432.2007 PubMed

77.

Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80(8 Suppl):1529–1537PubMed

78.

Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G, D’Souza-Schorey C (2009) ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol 19(22):1875–1885. doi:10.1016/j.cub.2009.09.059 PubMedCentralPubMed

79.

Dolo V, Ginestra A, Cassara D, Violini S, Lucania G, Torrisi MR, Nagase H, Canevari S, Pavan A, Vittorelli ML (1998) Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res 58(19):4468–4474PubMed

80.

Dolo V, D’Ascenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A, Vittorelli ML, Canevari S, Pavan A (1999) Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 17(2):131–140PubMed

81.

Ginestra A, La Placa MD, Saladino F, Cassara D, Nagase H, Vittorelli ML (1998) The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res 18(5A):3433–3437PubMed

82.

Dolo V, Ginestra A, Ghersi G, Nagase H, Vittorelli ML (1994) Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol 26(2):173–180PubMed

83.

Wysoczynski M, Ratajczak MZ (2009) Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer 125(7):1595–1603. doi:10.1002/ijc.24479 PubMedCentralPubMed

84.

Dashevsky O, Varon D, Brill A (2009) Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer 124(8):1773–1777. doi:10.1002/ijc.24016 PubMed

85.

Angelucci A, D’Ascenzo S, Festuccia C, Gravina GL, Bologna M, Dolo V, Pavan A (2000) Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis 18(2):163–170PubMed

86.

Giusti I, D’Ascenzo S, Millimaggi D, Taraboletti G, Carta G, Franceschini N, Pavan A, Dolo V (2008) Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 10(5):481–488PubMedCentralPubMed

87.

Castellana D, Zobairi F, Martinez MC, Panaro MA, Mitolo V, Freyssinet JM, Kunzelmann C (2009) Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res 69(3):785–793. doi:10.1158/0008-5472.CAN-08-1946 PubMed

88.

Ma J, Cai W, Zhang Y, Huang C, Zhang H, Liu J, Tang K, Xu P, Katirai F, Zhang J, He W, Ye D, Shen GX, Huang B (2013) Innate immune cell-derived microparticles facilitate hepatocarcinoma metastasis by transferring integrin alpha(M)beta(2) to tumor cells. J Immunol 191(6):3453–3461. doi:10.4049/jimmunol.1300171 PubMed

89.

Poste G, Nicolson GL (1980) Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc Natl Acad Sci U S A 77(1):399–403PubMedCentralPubMed

90.

Hao S, Ye Z, Li F, Meng Q, Qureshi M, Yang J, Xiang J (2006) Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes. Exp Oncol 28(2):126–131PubMed

91.

Hood JL, San RS, Wickline SA (2011) Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 71(11):3792–3801. doi:10.1158/0008-5472.CAN-10-4455 PubMed

92.

Rana S, Malinowska K, Zoller M (2013) Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 15(3):281–295PubMedCentralPubMed

93.

Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18(6):883–891. doi:10.1038/nm.2753 PubMedCentralPubMed

94.

Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL (2012) Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151(7):1542–1556. doi:10.1016/j.cell.2012.11.024 PubMed

95.

Ji H, Greening DW, Barnes TW, Lim JW, Tauro BJ, Rai A, Xu R, Adda C, Mathivanan S, Zhao W, Xue Y, Xu T, Zhu HJ, Simpson RJ (2013) Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics 13(10–11):1672–1686. doi:10.1002/pmic.201200562 PubMed

96.

Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470–1476. doi:10.1038/ncb1800 PubMedCentralPubMed

97.

Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P, Rank A, Gohring P, Thaler CJ, Friese K, Bauerfeind I (2008) Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res 28(2A):1107–1112PubMed

98.

Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R, Zembala M, Barbasz J, Czupryna A, Szczepanik A (2010) Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother 59(6):841–850. doi:10.1007/s00262-009-0808-2 PubMed

99.

Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Ryu KW, Bae JM, Kim S (2003) Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 39(2):184–191PubMed

100.

Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM, Oudard S (2009) Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 56(3):479–484. doi:10.1016/j.eururo.2008.06.038 PubMed

101.

Fleitas T, Martinez-Sales V, Vila V, Reganon E, Mesado D, Martin M, Gomez-Codina J, Montalar J, Reynes G (2012) Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One 7(10):e47365. doi:10.1371/journal.pone.0047365 PubMedCentralPubMed

102.

Reynes G, Vila V, Fleitas T, Reganon E, Font de Mora J, Jorda M, Martinez-Sales V (2013) Circulating endothelial cells and procoagulant microparticles in patients with glioblastoma: prognostic value. PLoS One 8(7):e69034. doi:10.1371/journal.pone.0069034 PubMedCentralPubMed

103.

Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, Lee H (2012) Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 18(12):1835–1840. doi:10.1038/nm.2994 PubMedCentralPubMed

104.

Geddings JE, Mackman N (2013) Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 122(11):1873–1880. doi:10.1182/blood-2013-04-460139 PubMedCentralPubMed

105.

Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, Mullauer L, Gnant M, Scheithauer W, Pabinger I (2013) Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Investig 43(3):277–285. doi:10.1111/eci.12042

106.

Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309–322. doi:10.1016/j.ccr.2012.02.022 PubMed

107.

Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J, Reca R, Janowska-Wieczorek A, Ratajczak MZ (2002) Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 30(5):450–459PubMed

108.

Janowska-Wieczorek A, Majka M, Kijowski J, Baj-Krzyworzeka M, Reca R, Turner AR, Ratajczak J, Emerson SG, Kowalska MA, Ratajczak MZ (2001) Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 98(10):3143–3149PubMed

109.

Mesri M, Altieri DC (1998) Endothelial cell activation by leukocyte microparticles. J Immunol 161(8):4382–4387PubMed

110.

Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR (2003) Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res 63(15):4331–4337PubMed

111.

Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, Lv M, Li D, Katirai F, Shen GX, Zhang G, Feng ZH, Ye D, Huang B (2012) Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun 3:1282. doi:10.1038/ncomms2282 PubMed

112.

Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51(4):691–743PubMed

113.

Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT (2002) Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 10(7):539–548. doi:10.1080/1061186021000072447 PubMed

114.

Park JW, Benz CC, Martin FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31(6 Suppl 13):196–205PubMed

115.

Toledano Furman NE, Lupu Haber Y, Bronshtein T, Kaneti L, Letko N, Weinstein E, Baruch L, Machluf M (2013) Reconstructed stem cell nano-ghosts: a natural tumor targeting platform. Nano Lett. doi:10.1021/nl401376w PubMed

Title: Small But Mighty: Microparticles as Mediators of Tumor Progression
Authors: Tali Voloshin
Ella Fremder
Yuval Shaked
Publication date: 01-08-2014
Publisher: Springer Netherlands
Published in: Cancer Microenvironment / Issue 1-2/2014
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-014-0144-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2014

Microparticles mediated cross-talk between tumoral and endothelial cells promote the constitution of a pro-metastatic vascular niche through Arf6 up regulation

Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy

T Cell Avidity and Tumor Immunity: Problems and Solutions

Macrophage Infiltration in Tumor Stroma is Related to Tumor Cell Expression of CD163 in Colorectal Cancer

Detection of Estrogen-Independent Growth-Stimulating Activity in Breast Cancer Tissues: Implication for Tumor Aggressiveness

Extracellular Matrix Protein Laminin Induces Matrix Metalloproteinase-9 in Human Breast Cancer Cell Line MCF-7

Keynote webinar | Spotlight on antibody–drug conjugates in cancer